Developmental therapeutics for inflammatory breast cancer: Biology and translational directions

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, which accounts for approximately 3% of cases of breast malignancies. Diagnosis relies largely on its clinical presentation, and despite a characteristic phenotype, underlying molecular mechanisms are poorly understood. Unique clinical presentation indicates that IBC is a distinct clinical and biological entity when compared to non-IBC. Biological understanding of non-IBC has been extrapolated into IBC and targeted therapies for HER2 positive (HER2+) and hormonal receptor positive non-IBC led to improved patient outcomes in the recent years. This manuscript reviews recent discoveries related to the underlying biology of IBC, clinical progress to date and suggests rational approaches for investigational therapies.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-12-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.13778PMID 27926493PMCID 5355355
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract P4-13-18: A phase I study of romidepsin in combination with nab-paclitaxel in patients with metastatic HER-2 negative inflammatory breast cancer (IBC)

  2016cited by this paper
• Is Personalized Medicine Here?

  2016cited by this paper
• Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

  2016cited by this paper
• Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

  2016influential reference
• Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

  2016cited by this paper
• Abstract P5-04-02: The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

  2016cited by this paper
• Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors

  2016influential reference
• Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

  2016cited by this paper
• UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research

  2015cited by this paper
• Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model

  2015cited by this paper
• SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

  2015cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

  2015cited by this paper
• The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy

  2015cited by this paper
• Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.

  2015cited by this paper
• Abstract P2-04-02: Identifying molecular targets and mechanisms of treatment resistance in inflammatory breast cancer (IBC) using reverse-phase protein microarrays (RPMA)

  2015cited by this paper
• Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

  2014cited by this paper
• In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

  2014cited by this paper
• Incidence of Inflammatory Breast Cancer in Women, 1992–2009, United States

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014influential reference
• AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

  2014cited by this paper
• Exomics and immunogenics

  2014cited by this paper
• Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

  2014cited by this paper
• Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration

  2014cited by this paper
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment

  2014cited by this paper
• Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

  2014cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells

  2013cited by this paper
• Presence of anaplastic lymphoma kinase in inflammatory breast cancer

  2013cited by this paper
• The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.

  2013cited by this paper
• PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.

  2013cited by this paper
• Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

  2013cited by this paper
• Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

  2013cited by this paper
• EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells

  2013cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013influential reference
• Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers

  2013cited by this paper
• Molecular Pathways Molecular Pathways : JAK / STAT Pathway : Mutations , Inhibitors , and Resistance

  2013cited by this paper
• HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

  2013cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Identifying factors that impact survival among women with inflammatory breast cancer.

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

  2012cited by this paper
• A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

  2012cited by this paper
• Targeting the interleukin-6/Jak/stat pathway in human malignancies.

  2012cited by this paper
• Angiogenesis , Metastasis , and the Cellular Microenvironment Regulation of In fl ammatory Breast Cancer Cell Invasion through Akt 1 / PKB a Phosphorylation of RhoC GTPase

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome

  2011cited by this paper
• HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

  2011cited by this paper
• Knock‐down of amphiregulin inhibits cellular invasion in inflammatory breast cancer

  2011cited by this paper
• High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes

  2011cited by this paper
• International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.

  2010cited by this paper
• EGFR/Met association regulates EGFR TKI resistance in breast cancer

  2010cited by this paper
• Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination

  2010cited by this paper
• Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome

  2010cited by this paper
• Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

  2010cited by this paper
• Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers

  2010cited by this paper
• Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer

  2009cited by this paper
• Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

  2009cited by this paper
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

  2009cited by this paper
• Targeting the phosphoinositide 3-kinase pathway in cancer

  2009cited by this paper
• Phase I Trial of Pazopanib in Patients with Advanced Cancer

  2009cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• The epidemiology of inflammatory breast cancer.

  2008cited by this paper
• Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

  2008cited by this paper
• EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

  2007cited by this paper
• Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer

  2007cited by this paper
• The Polycomb group protein EZH2 directly controls DNA methylation

  2007influential reference
• Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays

  2007cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression

  2006cited by this paper
• Epidemiology of Inflammatory Breast Cancer (IBC)

  2006cited by this paper
• Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review.

  2006cited by this paper
• The Polycomb group protein EZH2 directly controls DNA methylation

  2006cited by this paper
• Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

  2006cited by this paper
• Clinical Aspects of Inflammatory Breast Cancer

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer

  2006cited by this paper

• Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer

  2026cites this paper
• Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.

  2025cites this paper
• Multifunctional role of the tumor associated monocytes/macrophages in the metastatic potential of inflammatory breast cancer.

  2024cites this paper
• Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers

  2024cites this paper
• Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target

  2023cites this paper
• Synergistic effects of inhibitors targeting PI3K and Aurora Kinase A in preclinical inflammatory breast cancer models

  2023cites this paper
• Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients

  2021cites this paper
• The CD151‐midkine pathway regulates the immune microenvironment in inflammatory breast cancer

  2020cites this paper
• Inflammatorisches Mammakarzinom

  2020cites this paper
• ERBB4 promotes the progression of inflammatory breast cancer through regulating PDGFRA

  2020cites this paper
• NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer

  2020cites this paper
• Chiral resolution of a caged xanthone and evaluation across a broad spectrum of breast cancer subtypes.

  2019cites this paper
• Inflammatory Breast Cancer: Diagnostic, Molecular and Therapeutic Considerations

  2019cites this paper
• XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

  2018cites this paper
• In vitro vascularized tumor platform for modeling breast tumor stromal interactions and characterizing the subsequent response

  2018cites this paper
• An Apparent Diffusion Coefficient Histogram Method Versus a Traditional 2-Dimensional Measurement Method for Identifying Non–Puerperal Mastitis From Breast Cancer at 3.0 T

  2018cites this paper
• Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies

  2018cites this paper
• In vitro vascularized tumor platform for modeling tumor‐vasculature interactions of inflammatory breast cancer

  2018cites this paper
• A history of exploring cancer in context

  2018cites this paper
• A Case of Inflammatory Breast Cancer That Expanded to the Contralateral Side Postoperatively

  2017cites this paper
• Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference

  2017cites this paper
• EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer

  2017cites this paper